Cargando…

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron

Omicron was designated by the WHO as a VOC on 26 November 2021, only 4 days after its sequence was first submitted. However, the impact of Omicron on current antibodies and vaccines remains unknown and evaluations are still a few weeks away. We analysed the mutations in the Omicron variant against e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Ye-Fan, Hu, Jing-Chu, Chu, Hin, Yau, Thomas, Zhang, Bao-Zhong, Huang, Jian-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876352/ https://www.ncbi.nlm.nih.gov/pubmed/35215983 http://dx.doi.org/10.3390/v14020390

Ejemplares similares

Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation
por: Das, Nabarun Chandra, et al.
Publicado: (2023)

Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge
por: Scotto, Riccardo, et al.
Publicado: (2022)

Pathogenicity of SARS‐CoV‐2 Omicron
por: Chu, Hin, et al.
Publicado: (2022)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

Development of novel monoclonal antibodies against nsp12 of SARS-CoV-2
por: Machitani, Mitsuhiro, et al.
Publicado: (2022)

Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
por: Gentile, Ivan, et al.
Publicado: (2021)

Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron
por: Zhou, Bing, et al.
Publicado: (2022)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
por: Wen, Kun, et al.
Publicado: (2023)

Antibody evasion properties of SARS-CoV-2 Omicron sublineages
por: Iketani, Sho, et al.
Publicado: (2022)

Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants
por: Hu, Ye-Fan, et al.
Publicado: (2022)

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
por: Mazzaferri, Fulvia, et al.
Publicado: (2022)

The potency and synergy of plant‐made monoclonal antibodies against the BA.5 variant of SARS‐CoV‐2
por: Sun, Haiyan, et al.
Publicado: (2023)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
por: Schulz, Sebastian R., et al.
Publicado: (2022)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
por: Ariën, Kevin K., et al.
Publicado: (2022)

Altered host protease determinants for SARS-CoV-2 Omicron
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2023)

Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies
por: Kang, Hyangju, et al.
Publicado: (2022)

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
por: Case, James Brett, et al.
Publicado: (2022)

A novel plant‐made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS‐CoV‐2 Omicron variant
por: Jugler, Collin, et al.
Publicado: (2022)

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
por: Park, Young-Jun, et al.
Publicado: (2022)

Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants
por: Zakir, Tasnim Saifudin, et al.
Publicado: (2022)

A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
por: Zhou, Biao, et al.
Publicado: (2022)

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
por: Touret, Franck, et al.
Publicado: (2023)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
por: Shuai, Huiping, et al.
Publicado: (2023)

Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2
por: Fiaschi, Lia, et al.
Publicado: (2022)

Surface electrostatic shift on spike protein decreased antibody activities against SARS-CoV-2 Omicron variant
por: Yuan, Shu, et al.
Publicado: (2022)

Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China
por: Zhang, Huan, et al.
Publicado: (2022)

Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
por: Zheng, Qianqian, et al.
Publicado: (2022)

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
por: Wang, Qian, et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.2.75 Variant May Be Much More Infective than Preexisting Variants Based on In Silico Model
por: Sugano, Aki, et al.
Publicado: (2022)

Striking antibody evasion of SARS-CoV-2 Omicron sub-lineages BQ.1.1, XBB.1 and CH.1.1
por: Ju, Bin, et al.
Publicado: (2023)

Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
por: Tao, Kaiming, et al.
Publicado: (2022)

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies
por: Zhong, Chaojie, et al.
Publicado: (2021)

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
por: Pérez-Then, Eddy, et al.
Publicado: (2022)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a200rsc1doebo9igddl082ec6d